Exchange: NYSE
Industry: Drug Manufacturers/Major
Last Trade: 4:01 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.23 | 1.14 | 7.89 |
| EPS, GAAP | 0.48 | 0.94 | -48.94 |
| Consensus Estimate | 1.22 | 1.21 | 0.83 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 5.54 | 5.57 | -0.54 |
| EPS, GAAP | 3.80 | 4.26 | -10.80 |
| Consensus Estimate | 5.44 | NA | NA |
| NVS | Industry Average | |
| P/E (TTM) | 14.78 | 17.80 |
| P/E (Forward) | 10.17 | 13.00 |
| PEG Ratio | 2.13 | 2.45 |
| Price/Sales | 2.28 | 2.54 |
| Beta | 0.51 | 0.57 |
| 10:50 AM | 2/7/2012 | US Judge Rules For FDA In Generic Lovenox Case |
| 6:14 PM | 1/31/2012 | FDA Grants Novartis Cancer Drug Added Approval |
| 2/9/2012 | FDA Sets Shortcut Path for Biosimilar Drugs (WSJ.com) |
| 2/7/2012 | Glaxo Has Been Repatriating Euro-Zone Cash (WSJ.com) |
| 2/7/2012 | Judge Rules for FDA in Generic Lovenox Case (WSJ.com) |
| 2/6/2012 | Teva Downgraded: Upside Looks Limited (Barrons.com) |
| 2/5/2012 | Ways to Bet on a Rebound in Europe (WSJ.com) |
| 2/2/2012 | Merck Shares Down After Mixed 4Q Results (Barrons.com) |
| 2/1/2012 | Vertex gains FDA approval for cystic fibrosis treatment Kalydeco. (The Motley Fool) |
| 2/1/2012 | No Illumina-tion for Roche (WSJ.com) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
